XML 103 R14.htm IDEA: XBRL DOCUMENT
v3.19.3.a.u2

Disposition | 3 Months Ended
--- | ---
Dec. 28, 2019
Discontinued Operations and Disposal Groups [Abstract] |
Dispositions | Disposition Sale of Medical Aesthetics - Assets Held-for-Sale On November 20, 2019, the Company entered into a definitive agreement to sell its Medical Aesthetics business to Clayton Dubilier & Rice ("CD&R") for a sales price of $205.0 million in cash, less certain adjustments. The sale was completed on December 30, 2019, and the Company received cash proceeds of $153.4 million. The sale price remains subject to adjustment upon finalization pursuant to the terms of the definitive agreement. The Company has agreed to provide certain transition services for three to fifteen months, depending on the nature of the service. As a result of this transaction, the Medical Aesthetics asset group was designated as assets held-for-sale in the first quarter of fiscal 2020. Pursuant to ASC 360, asset groups under this designation are required to be recorded at fair value less costs to sell. Based on the terms in the agreement of the sales price and formula for net working capital and related adjustments, its estimate of the fair value for transition services which must be carved out of the sale proceeds, and liabilities the Company will retain or for which it has agreed to indemnify CD&R, the Company recorded an impairment charge of $30.2 million in the first quarter of fiscal 2020. The impairment charge was allocated to Medical Aesthetics long-lived assets, of which $25.8 million was allocated to cost of product revenues and $4.4 million to operating expenses. Assets held-for sale comprise the following as of December 28, 2019:
Assets: |  | December 28, 2019
Cash |  | $ | 10.7 |
Accounts Receivable |  | 59.6 |
Inventory |  | 90.6 |
Prepaid expenses and other current assets |  | 7.7 |
Property, plant, and equipment |  | 4.0 |
Intangible assets |  | 28.2 |
Other assets |  | 9.8 |
Total assets held-for-sale |  | $ | 210.6 |
Liabilities: |  |
Accounts payable |  | $ | 12.3 |
Accrued expenses |  | 49.0 |
Deferred revenue |  | 16.6 |
Total liabilities held-for-sale |  | $ | 77.9 |
The Company has determined that this disposal did not qualify as a discontinued operation as the sale of the Medical Aesthetics business was deemed to not be a strategic shift having or will have a major effect on the Company's operations and financial results.

X
- References No definition available. + Details
Name: | us-gaap_DiscontinuedOperationsAndDisposalGroupsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for business combinations, including leverage buyout transactions (as applicable), and divestitures. This may include a description of a business combination or divestiture (or series of individually immaterial business combinations or divestitures) completed during the period, including background, timing, and assets and liabilities recognized and reclassified or sold. This element does not include fixed asset sales and plant closings. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 205 -SubTopic 20 -URI http://asc.fasb.org/subtopic&trid=2122178 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 805 -URI http://asc.fasb.org/topic&trid=2303972 + Details
Name: | us-gaap_MergersAcquisitionsAndDispositionsDisclosuresTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration